havrix 1440 vaccine
glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml; ; hepatitis a vaccine 1440 eu/ml - suspension for injection - 1440 eu/ml - active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.
pneumovax 23 vaccine
merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.
menitorix powder and solvent for solution for injection. haemophilus type b and meningococcal group c conjugate vaccine
glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated
pentavac diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus influenzae type b co
sanofi pasteur - purified diphtheria toxoid ph. eur.; purified tetanus toxoid; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus; haemophilus influenzae type b, conjugate with tetanus protein - powder for suspension for injection - 0.5 millilitre(s) - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus
porcilis pcv vaccine
intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen - misc. vaccines or anti sera - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 2.0 mg/2ml - immunotherapy
apvma veterinary use permit 12530- pythium vaccine/ horses/ pythium spp
apvma permit - vaccine - pythium spp. - vaccine
apvma veterinary use permit 12551- autogenous staphylococcus hyicus vaccine/ pigs/ greasy pig disease.
apvma permit - vaccine - greasy pig - vaccine
apvma veterinary use permit 12552- custom autogenous haemophilus parasuis vaccine/ pigs/ glassers disease
apvma permit - vaccine - glassers - vaccine
apvma veterinary use permit 12579- custom haemophilus parasuis inactivated vaccine for pigs/ pigs/ protection against haemophilu
apvma permit - vaccine - glassers - vaccine
apvma veterinary use permit 13756- custom pig hps vaccine/ pigs/ pneumonia
apvma permit - vaccine - glassers+pasteurella multocida+vaccine - streptococcus - vaccine